Cue Biopharma (CUE) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Journey Medical (DERM) over the past year, losing 0.2% versus a loss of 21.2%. Journey Medical is the larger company by market cap ($167.9 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | DERM |
|---|---|---|
| Share price | $22.51 | $5.95 |
| Market cap | $163.52M | $167.94M |
| 1-day change | -2.72% | -3.41% |
| YTD return | +146.01% | -22.83% |
| 1-year return | -0.22% | -21.19% |
| 5-year return | -94.04% | — |
| EPS (TTM) | $-29.59 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $9.56 |
| 52-week low | $4.98 | $4.31 |
| Distance from 52-week high | -50.53% | -37.73% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +290.94% | +131.09% |
| Average volume | 269.82K | 181.79K |
| Shares outstanding | 7.26M | 22.22M |
| Employees | 29 | 58 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed DERM by 21.0 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Healthcare · Drug Manufacturers - Specialty & Generic · 58 employees
CUE vs DERM FAQ
Which is bigger, Cue Biopharma or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $167.94M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or DERM?
CUE returned -0.22% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Journey Medical in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Cue Biopharma and Drug Manufacturers - Specialty & Generic for Journey Medical.